Introduction Current regulatory guidelines for assessing the risk of QT prolongation include
in vitro assays assessing drug effects on the human ether-à-go-go-related (hERG; also
known as Kv11. 1) channel expressed in cell lines. These assays are typically conducted at
room temperature to promote the ease and stability of recording hERG currents. However,
the new Comprehensive in vitro Proarrhythmia Assay (CiPA) paradigm proposes to use an
in silico model of the human ventricular myocyte to assess risk, requiring as input hERG …